VZ185

Overview

VZ185 is a BRD9 and BRD7 PROTAC degrader, with DC 50 values of 1.76 nM and 4.5 nM, respectively, in RI-1 cells; and DC 50 values of 4 nM and 34 nM, respectively, in HEK293 cells. VZ185 hijacks the CRL2 VHL E3 ubiquitin ligase complex to induce ubiquitination and subsequent proteasomal degradation of BRD9 and BRD7 . VZ185 can be used in research related to acute myeloid eosinophilic leukemia and malignant rhabdoid tumors. (Pink: BRD9 and BRD7 ligand ( HY-111905A ); Blue: VHL ligand ( HY-125905 ); Black: linker).

Application

Products | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Epigenetic Reader Domain

Product Information

• Catalog No.: HY-114322
• CAS No.: 2306193-61-1
• Molecular Formula: C53H67FN8O8S
• Molecular Weight: 995.21
• Purity: 99.95%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (5.02 mM); Clear solution
• Availability: In-stock

Source

Original product source